Login
Targeting EZH2 and EGFR Therapeutic Vulnerabilities of TNBC with a Single Chemical Entity Confers Preclinical Treatment Advantage
Utilizing medicinal chemistry approach, Datta and colleagues demonstrate that EZH2-EGFR dual targeting halts protein translation in TNBC and inhibits tumor growth and metastasis in preclinical animal models.
